Tarsa Therapeutics

Philadelphia, United States Founded: 2009 • Age: 17 yrs
Oral treatments for postmenopausal osteoporosis are developed.

About Tarsa Therapeutics

Tarsa Therapeutics is a company based in Philadelphia (United States) founded in 2009.. Tarsa Therapeutics has raised $76.69 million across 9 funding rounds from investors including Square 1 Bank, Oxford Finance and MVM Partners. The company has 2 employees as of September 30, 2017. Tarsa Therapeutics offers products and services including TBRIA. Tarsa Therapeutics operates in a competitive market with competitors including Rani Therapeutics, Zosano Pharma, Sojournix, Flowbone and Radius Recycling, among others.

  • Headquarter Philadelphia, United States
  • Employees 2 as on 30 Sep, 2017
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Legal Name Tarsa Therapeutics, Inc.
Operational Areas
Healthcare → Healthcare Products & Supplies
Healthcare → Health Technology & Digital Health
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $76.69 M (USD)

    in 9 rounds

  • Latest Funding Round
    $549.86 K (USD), Series B

    Jul 24, 2017

  • Investors
  • Employee Count
    2

    as on Sep 30, 2017

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Tarsa Therapeutics

Tarsa Therapeutics offers a comprehensive portfolio of products and services, including TBRIA. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Oral calcitonin formulation for treating postmenopausal osteoporosis effectively.

Funding Insights of Tarsa Therapeutics

Tarsa Therapeutics has successfully raised a total of $76.69M across 9 strategic funding rounds. The most recent funding activity was a Series B round of $549.86 thousand completed in July 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 9
  • Last Round Series B — $549,858
  • First Round

    (20 Oct 2009)

  • Investors Count 7
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2017 Amount Series B - Tarsa Therapeutics Valuation

investors

Jan, 2017 Amount Series B - Tarsa Therapeutics Valuation

investors

Jul, 2016 Amount Debt – Conventional - Tarsa Therapeutics Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Tarsa Therapeutics

Tarsa Therapeutics has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Square 1 Bank, Oxford Finance and MVM Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Venture debt firm focused on the life sciences sector
Founded Year Domain Location
Multi-stage investment firm invests in healthcare and life sciences companies
Founded Year Domain Location
-
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Tarsa Therapeutics

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Tarsa Therapeutics

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Tarsa Therapeutics Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Tarsa Therapeutics

Tarsa Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Rani Therapeutics, Zosano Pharma, Sojournix, Flowbone and Radius Recycling, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Technology for oral delivery of large drug molecules is developed.
domain founded_year HQ Location
Develops innovative transdermal drug delivery technologies for various therapeutic applications.
domain founded_year HQ Location
Online platform offering gaming agency with registration, login, and promotional features.
domain founded_year HQ Location
Injectable biomaterial is developed for osteoporosis bone treatment.
domain founded_year HQ Location
Steel is manufactured and scrap metal is recycled.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Tarsa Therapeutics

Frequently Asked Questions about Tarsa Therapeutics

When was Tarsa Therapeutics founded?

Tarsa Therapeutics was founded in 2009.

Where is Tarsa Therapeutics located?

Tarsa Therapeutics is headquartered in Philadelphia, United States. It is registered at Philadelphia, Pennsylvania, United States.

Is Tarsa Therapeutics a funded company?

Tarsa Therapeutics is a funded company, having raised a total of $76.69M across 9 funding rounds to date. The company's 1st funding round was a Debt – Conventional of $1.2M, raised on Oct 20, 2009.

How many employees does Tarsa Therapeutics have?

As of Sep 30, 2017, the latest employee count at Tarsa Therapeutics is 2.

What does Tarsa Therapeutics do?

Tarsa Therapeutics was founded in 2009 and is located in Philadelphia, United States. Focus is placed on the biotechnology sector, where oral formulations for postmenopausal osteoporosis are developed. TBRIA, featuring calcitonin-salmon in delayed-release tablets, has been produced using recombinant DNA technology. FDA approval is currently being pursued for this treatment option. Operations center on advancing peptide-based therapies for bone health conditions.

Who are the top competitors of Tarsa Therapeutics?

Tarsa Therapeutics's top competitors include Rani Therapeutics, Radius Recycling and Flowbone.

What products or services does Tarsa Therapeutics offer?

Tarsa Therapeutics offers TBRIA.

Who are Tarsa Therapeutics's investors?

Tarsa Therapeutics has 7 investors. Key investors include Square 1 Bank, Oxford Finance, MVM Partners, Foresite Capital, and Quaker Partners Management.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available